سعر جرانوسيت 34 م وحدة فيال 2026

Granocyte (lenograstim 34 million IU/ml) vial by Sanofi; recombinant G-CSF used to reduce neutropenia and mobilise peripheral blood progenitor cells.

• Reduction of the duration of neutropenia in patients with non-myeloid malignancy undergoing myeloablative therapy followed by bone marrow transplantation at increased risk of prolonged severe neutropeniaPopulation: Adults, adolescents and children older than 2 yearsMHRA / electronic medicines compendium (emc)
• Reduction of the duration of severe neutropenia and its complications in patients on established cytotoxic chemotherapy associated with significant incidence of febrile neutropeniaPopulation: Adults, adolescents and children older than 2 yearsMHRA / electronic medicines compendium (emc)
• Mobilisation of peripheral blood progenitor cells (patients and healthy donors)Population: Adults, adolescents and children older than 2 yearsMHRA / electronic medicines compendium (emc)

• Hypersensitivity to lenograstim or excipients. Not to increase cytotoxic chemotherapy dose intensity beyond established regimens; not concurrently with cytotoxic chemotherapy.International label, same formulation · MHRA / electronic medicines compendium (emc)
• Not to be given to patients with myeloid malignancy other than de novo AML, de novo AML below 55 years, or de novo AML with good cytogenetics (t(8;21), t(15;17), inv(16)).International label, same formulation · MHRA / electronic medicines compendium (emc)

• G-CSF may promote myeloid cell growth; not established in myelodysplasia, secondary AML or CML—should not be used in these. Increased risk of secondary myeloid leukaemia/MDS reported in children with ALL.International label, same formulation · MHRA / electronic medicines compendium (emc)
• Splenomegaly and very rare splenic rupture reported; monitor spleen size and consider rupture with left upper abdominal or shoulder-tip pain. Capillary leak syndrome, interstitial pneumonia/ARDS, sickle cell crisis and aortitis have been reported.International label, same formulation · MHRA / electronic medicines compendium (emc)

• No adequate data in pregnant women; animal studies showed reproductive toxicity; should not be used during pregnancy unless clearly necessary.International label, same formulation · MHRA / electronic medicines compendium (emc)
• Unknown whether lenograstim is excreted in human milk; breastfeeding should be discontinued during therapy.International label, same formulation · MHRA / electronic medicines compendium (emc)

English text not available for this section.